ArticleJournal of surgical case reports2025
Salvage resection after immunotherapy for giant undifferentiated pleomorphic sarcoma of the chest wall.
Article in Journal of surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cytokeratin-Positive Pleomorphic Chest Wall Sarcoma Mimicking MPNST: A Case Report.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a rare case of primary undifferentiated pleomorphic sarcoma (UPS) of the chest wall in a 45-year-old male, initially diagnosed as sarcomatoid pleural mesothelioma via computed tomography (CT)-guided biopsy. CT revealed a large tumor measuring 13 × 12 cm occupying the left thoracic cavity, with extensive invasion into the left first through fifth ribs and the adjacent lung parenchyma. The patient was referred to our hospital and treated with a combination of nivolumab and ipilimumab, resulting in marked tumor regression. Upon reevaluation, the diagnosis was revised to sarcoma, and the patient subsequently underwent salvage surgery, including resection of the left upper lung lobe and first through fifth ribs. Histopathology confirmed tumor mutational burden-high UPS. The patient has remained disease-free for two and a half years postoperatively. This case demonstrates the potential efficacy of immune checkpoint inhibitors in multimodal treatment for select cases of chest wall UPS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.